Cetya Therapeutics, Inc. is a Delaware C-Corporation formed in 2012 to develop histone deacetylase inhibitors (HDACi) based on analogs of largazole. Some of these analogs incorporate receptor ligands, which enable them to target specific cell types or tumors. This targeting approach is unique for HDACi and, together with increased potency and selectivity, differentiates Cetya’s compounds. More than 30 largazole analogs have been synthesized, some with best-in-class HDACi profiles, including:
- Biochemical and cell-based potency
- Up-regulation of fetal hemoglobin expression
- In vivo anti-cancer activity
Cetya is seeking corporate partners to assist in advancing its largazole analog portfolio into clinical studies in a number of different therapeutic indications.
